Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up

Time to reflect: helping patients to understand the natural history of prostate cancer

“…10 The data we have do not show equivalence and treatment for most patients does not equate to cure, but the length of the disease is such that this may not matter to many. 11 What patients need is time and the chance to reflect on what they want and what their general level of health holds out to them over the next 15 or 20 years.…”

Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study

“…Early versus deferred endocrine treatment strategies have been investigated in a number of prospective, randomised trials [6,[15][16][17][18][19][20]. Immediate therapy can delay objective disease progression of PCa regardless of the clinical stage [6,[15][16][17][18][19][20]; However, this initial clinical benefit has not materialised into an improved PCa-specific survival in patients with localised PCa managed on WW or following curative intended therapy in patients without lymph node metastasis [6,15,16].…”

“…Immediate therapy can delay objective disease progression of PCa regardless of the clinical stage [6,[15][16][17][18][19][20]; However, this initial clinical benefit has not materialised into an improved PCa-specific survival in patients with localised PCa managed on WW or following curative intended therapy in patients without lymph node metastasis [6,15,16]. In contrast, early hormonal therapy has been demonstrated to improve both OS and PCa-specific survival in patients with locally advanced PCa or lymph node metastasis [17][18][19][20]. The Medical Research Council Prostate Cancer Working Party Investigators Group found an OS benefit of early ADT in 938 newly diagnosed patients with cT2-4 with or without metastasis compared to deferred ADT [17].…”

Radiothérapie chez la personne âgée, recommandations pour la pratique clinique pour les principales localisations : cancers du sein, de la prostate et gynécologiques

“…Isolément, elle ne diminue la mortalité due au cancer [60] et ses effets secondaires généraux doivent limiter ses indications chez le sujet âgé. Or elle est encore largement prescrite, probablement du fait de la facilité de prescription et de son effet sur la concentration d'antigène spécifique de la prostate, qui rassure à tort le patient et le médecin.…”